Therapeutic Insights
Filter News
Found 655 articles
-
“The recent progress of cystic fibrosis drugs has been amazing and, in my case, miraculous,” said Kelly Peters, who lives with cystic fibrosis. “The new drugs are not a cure, but they feel pretty close.”
-
BioSpace takes an in-depth look at the human immunodeficiency virus including research, drugs in the pipeline and treatments. Check out the free downloadable report.
-
*Achoo* Muddling through a stuffy, runny nose and itchy, watery eyes? You aren’t alone - over 17.6 million American adults (about 7.5%) experience allergic rhinitis (also called hay fever or seasonal allergies). Many different substances (called allergens) can trigger allergic rhinitis, such as ...
-
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...
-
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
-
Peanut allergy is the most common food allergy in children and that number has been rising – peanut allergy incidence increased 21 percent from 2010 to 2017. Almost 2.5 percent of children in the US are thought to have a peanut allergy, according to the American College of Allergy, Asthma, and Im...
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
Diadem Announces Publication of Clinical Study Confirming Its AlzoSure® Predict Blood Test Can Accurately Predict Progression to Alzheimer's Disease Six Years Before Diagnosis
5/16/2022
Diadem SpA announced publication of the results of a clinical validation study of its AlzoSure® Predict prognostic blood test for Alzheimer's disease.
-
Kansas City Based Health Care Startup Buys Digital Therapeutics Company Focused on Alzheimer's and Dementia
5/11/2022
Telememory Holding Corp., the makers of MoodSpark, has purchased Dthera Sciences, a pioneer in the digital therapeutics industry and leader in developing innovative quality of life therapies for those suffering from cognitive decline.
-
Eisai and Biogen have completed the rolling submission of a Biologics License Application for lecanemab drug to the U.S. Food and Drug Administration.
-
A recent study describes how researchers at the UK Research Institute at the University of Cambridge stumbled upon a potential target of dementia research.
-
Eisai completes rolling submission to the FDA of lecanemab for early Alzheimer's disease under the accelerated approval pathway
5/10/2022
BioArctic AB's partner Eisai announced that they have completed the rolling submission to the U.S. FDA of a Biologics License Application under the accelerated approval pathway for the investigational anti-amyloid beta protofibril antibody lecanemab, for the treatment of mild cognitive impairment due to Alzheimer's disease and mild AD with confirmed presence of amyloid pathology in the brain.
-
Athira Pharma announced the duration of its open-label study of fosgonimeton for the treatment of mild-to-moderate Alzheimer’s Disease (AD) has been increased from six months to eighteen months.
-
Emulate Announces Launch of Immune Cell Recruitment Application for the Colon Intestine-Chip to Aid in the Study of Inflammatory Bowel Disease
5/9/2022
Emulate, Inc. today announced its new colon immune cell recruitment application, enabling the most human-relevant preclinical assessment of inflammatory bowel disease (IBD) drug candidates.
-
Cognito Therapeutics Joins Digital Medicine Society’s (DiMe) Alzheimer's Disease and Related Dementias Project to Advance Next-Generation Clinical Measures
5/9/2022
Cognito Therapeutics today announced it has joined the Digital Medicine Society’s (DiMe) Alzheimer’s Disease and Related Dementias (ADRD) Digital Measures Development Project to support the advancement of its late-stage disease-modifying therapeutics pipeline for neurodegenerative diseases.
-
Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease
5/9/2022
Athira Pharma, Inc. today announced that it is extending the length of the current open label extension (OLEX) study for its Phase 3 LIFT-AD and Phase 2 ACT-AD studies of fosgonimeton.
-
May has been fruitful for research into the prevention and diagnosis of Alzheimer’s disease, the mechanisms behind early symptoms and potential treatments.
-
Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
5/5/2022
Alzamend Neuro, Inc. today announced that the first patient with mild to moderate Alzheimer’s disease (“Alzheimer’s”) has been dosed in a 12-month Phase IIA multiple ascending dose (“MAD”) study for dementia related to Alzheimer’s.
-
Fujirebio Diagnostics Lumipulse® G β-Amyloid Ratio (1-42/1-40) In Vitro Diagnostic Test Receives Marketing Authorization for the Assessment of Alzheimer’s Disease
5/5/2022
Fujirebio Diagnostics Lumipulse® G β-Amyloid Ratio (1-42/1-40) In Vitro Diagnostic Test Receives Marketing Authorization for the Assessment of Alzheimer’s Disease.
-
Denali Therapeutics, Inc. has announced that dosing has begun for participants of a Phase II clinical trial that intends to evaluate the potential of SAR443820 (DNL788) in patients with amyotrophic lateral sclerosis (ALS).